氯吡格雷用药时间对接受急诊介入治疗急性心肌梗死患者临床疗效的影响

Objective To evaluate effect of duration of clopidogrel use on clinical follow-up outcomes in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Methods A total of 214 patients with acute myocardial infarction undergoing primary percutaneous coronary intervention between January 2005 to December 2007 were enrolled. All patients were divided into two groups by duration of clopidogrel use; ＜1 year group (n=59) and ≥1 years group (n = 155). Baseline characteristics [age, gender, angiographic characteristics, Killip classification, LVEF (left ventricular ejection fraction) , CK (creatine kinase), CK-MB, CTnI (cardiac troponin-I), hemoglobin levels and history of hypertension, diabetes , hyperlipidemia, obesity and smoking ] of two groups were collected. Clinical follow-up end-point was major adverse cardiac event (MACE) including death, acute myocardial infarction, stent thrombosis and stent restenosis. Clinical follow-up duration was 41.6 ± 16.3 months. MACE occurred in 28 patients. Results Rates of male, infarction site .infarction relative artery, multi-vessel disease, Killip classification (class I) , aspirin use and history of smoking, obesity, hypertension and hyperlipidemia were not different ( P ＞ 0. 05) in duration of clopidogrel use ＜ 1 year group and ≥ 1 years group. Average LVEF, hemoglobin levels and rate of drug-eluting stents were significantly lower in duration of clopidogrel use ＜ 1 year group than that in duration of clopidogrel use ≥1 years group (P ＜0. 0001 ,P ＜0. 0001 ,P=0. 0065). Average CK、CK-MB.CTnI were significantly higher in duration of clopidogrel use ≥ 1 years group than that in duration of clopidogrel use ＜ 1 year group (P ＜ 0. 0001 ). Rate of diabetes and average age were significantly higher in duration of clopidogrel use ＜ 1 year group than that in duration of clopidogrel use ≥1 years group (P =0. 0190, P ＜0. 0001 ). Incidence of MACE in follow-up period was significantly lower in duration of clopidogrel use ≥1 years group than that in duration of clopidogrel use ＜ 1 year group (6.45% vs 30. 51% ,P ＜0. 01). After stopping clopidogrel use, incidence of MACE in follow-up period was significantly lower in duration of clopidogrel use ≥1 years group than that in duration of clopidogrel use ＜ 1 year group (2. 58% vs 20. 34% , P ＜ 0. 01 ) . Conclusion Primary percutaneous coronary intervention is an effective therapeutic method. Incidence of MACE in follow-up period was significantly lower in duration of clopidogrel use ≥1 years group than that in duration of clopidogrel use ＜ 1 year group. Duration of clopidogrel use may influence clinical outcomes in follow-up period in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention.     

Gender differences in efficacy of primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction

Background The clinical outcome of percutaneous coronary intervention （PCI） is poorer in women than that in men. This study aimed at comparing the impact of gender difference on the strategy of primary PCI in patients with acute ST-segment elevation myocardial infarction （STEMI）.
Methods Two hundred and fifty-nine patients with STEMI who underwent primary PCI within 12 hours of symptom onset were enrolled. The male group consisted of 143 men aged 〉55 years, and a female group included 116 women without age limitation. Procedural success was defined as residual stenosis 〈20% with thrombolysis in myocardial infarction flow grade 〉2 and without death, emergency bypass surgery or disabling cerebral events during the hospitalization. The rate of major adverse cardiac events （MACE）, including death, nonfatal myocardial infarction and target vessel revascularization during follow-up, was recorded.
Results Female patients were more hypertensive and diabetic and with fewer cigarette smokers than male counterparts. The prevalence of angiographic 3-vessel disease was higher in the female group, but the procedural success rate was comparable between the two groups （94.4% vs 92.2%）. The occurrence rate of MACE did not differ during the hospitalization （4.2% vs 6.0%, P=0.50）, but was significantly higher in the female group during follow-up （mean （16.0±11.2） months） than that in the male group （5.4% vs 0.7%, P=0.02）.
Conclusion Despite a similar success rate of primary PCI and in-hospital outcomes in both genders, female patients with acute STEMI still have a worse prognosis during the long-term follow-up.     

Effect of tirofiban plus clopidogrel and aspirin on primary percutaneous coronary intervention via transradial approach in patients with acute myocardial infarction

Background Aspirin and clopidogrel can improve myocardial reperfusion and alleviate myocardial injury during percutaneous coronary intervention （PCI）. Whether the addition of intravenous tirofiban during this procedure produces further benefit has not been clarified in ST segment elevation myocardial infarction （STEMI） patients. We evaluated this on STEMI patients who underwent primary PCI （p-PCI） via transradial artery approach. Methods Consecutive patients were randomized into tirofiban group （n=-72） or placebo group （n=-78）. Angiographic analysis included initial and final thrombolysis in myocardial infarction （TIMI） flow grade （TFG）, corrected TIMI frame count （CTFC） and TIMI myocardial perfusion grade （TMPG） of the thrombotic vessel. Platelet aggregation rate （PAR）, creatine phosphokinase （CPK）, CPK isoenzyme MB （CPK-MB） and troponin I levels were measured and TIMI definitions were used to assess bleeding complications. Left ventricular performance parameters were investigated with equilibrium radionuclide ventriculography. Major adverse cardiac events （MACE） were followed up for 6 months. Results The cases of TFG 0 and 1 before PCI, TFG 0 when first crossing of guide wire were less, and the cases of TFG 3 after PCI was more in tirofiban group than those in placebo group. The final CTFC was fewer and the incidence of no reflow phenomenon was lower, as well the percentage of final TFG 3 was higher in tirofiban group than those in placebo group （all P 〈0.05）. Mean peak CPK-MB was significantly lower, while the left ventricular performance parameters 1 week after PCI were much more improved in tirofiban group than those in the placebo group. PAR was significantly decreased shortly after tirofiban infusion. The incidence of 6-month MACE in tirofiban group was obviously lower than that in the placebo group. No statistical difference was noted between the two groups with regard to bleeding complications. Conclusions Intravenous tirofiban infusion, in additi     

替格瑞洛对急性ST段抬高型心肌梗死患者行急诊介入治疗的中期随访

Objective： To evaluate the safety and efficacy of antiplatelet therapy of ticagrelor on patients suffering from acute ST segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.Methods: In the study, 96 patients suffering from acute ST segment elevation myocardial infarction onset within 12 h undergoing primary percutaneous coronary intervention from May to October in 2013 were randomly divided into ticagrelor group (n=48) and clopidogrel group (n=48) by using the method of random number table. Ticagrelor and clopidogrel antiplatelet treatment were used before and after operation. Their baseline data, coronary artery disease characteristics, platelet count, adenosine diphosphate(ADP)-induced platelet inhibition rate by thrombelastograph after 5 days of treatment, the major adverse cardiovascular events of the follow up for 6 months and bleeding complications were observed and compared in the two groups. Results: The differences between the two groups of patients with their baseline data, the features of coronary artery lesions, platelet count before and after 5 days of treatment had no statistical significance (P>0.05). ADP induced platelet inhibition rate ［(80.2±10.7)%］ after 5 days of treatment in ticagrelor group was significantly higher than that in clopidogrel group ［(75.3±12.1)%, P<0.05］. The two groups of patients were followed up for 6 months, 8 cases of major adverse cardiovascular events occurred in clopidogrel group, 2 cases of major adverse cardiovascular events occurred in ticagrelor group, and there was significant difference between the two groups (P<0.05). The two groups (7 cases of 48 patients in ticagrelor group vs. 3 cases of 48 patients in clopidogrel group) had no statistically significant difference in bleeding complications (P>0.05).Conclusion: Antiplatelet therapy of ticagrelor on patients suffering from acute ST segment elevation myocardial infarction undergoing emergency PCI has good efficacy and safety.     

Outcomes of primary percutaneous coronary intervention for acute ST-elevation myocardial infarction in patients aged over 75 years

Background The optimal reperfusion strategy in elderly patients with ST-elevation myocardial infarction （STEMI） remains unclear. The purpose of this study was to evaluate the safety, in-hospital and one-year clinical outcomes for patients 〉75 years of age with STEMI receiving primary percutaneous coronary intervention （PCI）, compared with those treated by conservative approach. Methods One hundred and two patients 〉75 years of age with STEMI presented 〈12 hours were randomly allocated to primary PCI （n=50） or conservative therapy only （n=52）. The baseline characteristics, in-hospital outcome and major adverse cardiac events （MACE）, including death, non-fatal myocardial infarction and target vessel revascularization at one-year clinical follow-up were compared between the two groups. Results Age, gender distribution, risk factors for coronary artery disease, infarct site and clinical functional status were similar between the two groups, but the patients in primary PCI group received less low-molecular- weight heparin during hospitalization. Compared with conservative group, the patients in primary PCI group had significantly lower occurrence rate of re-infarction and death and shortened hospital stay. The composite endpoint for in-hospital survivals at 30-day follow-up was similar between the two groups, but one-year MACE rate was significantly lower in the primary PCI group （21.3% and 45.2%, P=0.029）. Left ventricular ejection fraction was not significantly changed in both groups during follow-up. Multivariate analysis revealed that primary PCI （OR=0.34, 95% CI： 0.21-0.69, P =0.03） improved MACE-free survival rate for STEMI patients aged 〉 75 years. Conclusion Our results indicated that primary PCI was safe and effective in reducing in-hospital mortality and one-year MACE rate for elderly patients with STEMI.     

左室射血分数对急诊冠状动脉介入治疗急性ST段抬高心肌梗死患者远期预后的影响

目的 评价左室射血分数(LVEF)对接受急诊冠状动脉介入治疗(PCI)急性ST段抬高心肌梗死患者临床预后的影响.方法 158例接受了急诊PCI急性ST段抬高心肌梗死患者纳入本研究,根据出院前的LVEF分为3组:≤40%(n=14)、41%～55%(n=46)和＞55%(n=98),临床随访平均(43.1±15.2)个月,主要不良心脏事件(MACE)发生15例.结果 3组在心肌梗死部位、梗死相关血管、单支血管病变、双支血管病变、CTnI、CK、CK-MB、高血压、糖尿病、高血脂、吸烟、肥胖、阿司匹林和氯吡格雷使用比例、氯吡格雷使用时间的差异均无统计学意义(均P＞0.05).在LVEF≤40%和41%～55%组,平均年龄显著高于LVEF＞55%组(P＜0.0001);在LVEF≤40%组,其三支病变的比例显著高于LVEF41%～55%和＞55%组(P=0.0036);在LVEF41%～55%组和＞55%组,其术后TIMI3级血流和完全血运重建的比例显著高于LVEF≤40%组(P=0.0099,P=0.0010),而Killip分级(Ⅱ,Ⅲ,Ⅳ级)的比例、平均的症状发作至球囊打开时间(SOTB)显著低于LVEF≤40%组(P=0.0100,P=0.0087).在LVEF≤40%和41%～55%组,其药物支架的比例显著低于LVEF＞55%组(P=0.0242).多因素Logistic回归分析显示,出院前LVEF是随访期总MACE发生的独立预测因素(P=0.0029),差异有统计学意义.随着LVEF的减低,在LVEF＞55%、41%～55%、≤40%组的随访期间总MACE发生率显著增加(6.12%比8.70%比35.71%,P=0.0019),随访期间总死亡和心性死亡的发生率也显著增加(1.02%比4.35%比21.43%,P=0.0090;1.02%比2.17%比14.29%,P=0.0060),差异有统计学意义.结论 在接受急诊PCI的急性ST段抬高心肌梗死患者,左室射血分数是其随访期MACE发生的独立预测因子,随着LVEF的减低,其随访期MACE发生率增加.

Abstract：

Objective To evaluate the effect of left ventricular ejection fraction (LVEF) on clinical outcomes in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Methods A total of 158 patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention between January 2005 to December 2007were enrolled. They were divided into three groups: LVEF ≤40% ( n = 14), LVEF 41% - 55 % ( n = 46)and LVEF ＞ 55% group ( n = 98 ). The clinical follow-up end-point was major adverse cardiac event (MACE) including death, acute myocardial infarction, stent thrombosis and stent restenosis. The clinical follow-up duration was 43.1 ± 15.2 months. MACE occurred in 15 patients. Results The rates of infarction site, infarction relative artery, 1-vessel disease, 2-vessel disease, hypertension, diabetes, hyperlipidemia,smoking, obesity and aspirin use were not different in three groups (P ＞0.05). Average CTnI, CK,CK-MB and duration of clopidogrel use were not different in three groups ( P ＞ 0. 05 ). The rate of 3-vessel disease was significantly higher in the LVEF≤40% group than that in the LVEF 41% -55% and LVEF ＞55% groups (P =0. 0036). The rates of TIMI flow grades (Grade Ⅲ ) and complete revascularization were significantly higher in the LVEF 41% -55% and LVEF ＞55% groups than that in the LVEF≤40% group ( P =0. 0099 ,P =0. 0010). The rates of Killip classification ( classes Ⅱ , Ⅲ, Ⅳ ) and average symptomonset-to balloon-time (SOTB) were significantly lower in the LVEF 41% -55% and LVEF ＞55% groups than that in the LVEF ≤ 40% group ( P = 0. 0100, P = 0. 0087 ). The rate of drug-eluting stents was significantly lower in the LVEF≤40% group and LVEF 41% -55% group than that in LVEF ＞55% group (P = 0. 0242). Logistic regression analysis showed that LVEF was independent predictor for MACE in the follow-up period ( P = 0. 0029 ) . With LVEF decrease, incidence of MACE in the follow-up period significantly increased in LVEF ＞55% group ,LVEF41% -55% group and LVEF≤40% group(6. 12% vs 8. 7% vs 35.71%, P = 0. 0019). Incidence of total death and cardiac death in the follow-up period significantly increased in LVEF ＞55% group ,LVEF41% -55% group and LVEF≤40% group( 1.02% vs 4.35% vs 21.43% ,P=0.0090;1.02% vs 2. 17 vs 14.29% ,P=0.0060). Conclusion In patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention,LVEF was independent predictor for MACE in the follow-up period. With LVEF decrease, incidence of MACE in the follow-up period significantly increased.     

急性心肌梗死患者血清脑钠肽与近期预后关系的临床研究

Objective To investigate relationship between serum level of brain natriuretic peptide (BNP)and short-term prognosis in patients with acute myocardial infarction(AMI).Methods Ninetynine patients with AMl with elevated S-T segment in electrocardiogram admitted to the department of cardiology,the Fourth Hospital of Jilin University,Changchun during January to December 2008 were divided into two groups.one with percutaneous transluminal coronary angioplasty(PTCA)or pereutaneous coronary intervention(PCI)(61 eases)and the other without PTCA(38 cases)as controls.Their serum levels of BNP were measured at admission, and one day and seven days after admission,respectively,and their main adverse cardiac events(MACE)were followed-up and recorded for 30 days.Results No significant differenee in serum BNP level between the patients at admission and one day after admission was found(P＜0.01).Seven days after admission,serum BNP level in PCI group was significantly lower than that in controls(P＜0.01),and occurrence of MACE was significantly lower in PCI group than that in controls(P＜0.05).Logistic regression analysis indicated that serum BNP level in PCI group seven days after admission was the uppermost predictor for MACE in patients with AMI in one month after onset(OR=1.026,95%CI 1.014-1.038,P＜0.01).Serum BNP level was significantly higher in patients with MACE seven days after admission than that in those without it(P＜0.01)during 30-day followup.Conclusion Serum level of BNP seven days after admission is associated with their short-term prognosisfor patients with AMI.     

急性心肌梗死患者血清脑钠肽与近期预后关系的临床研究

Objective To investigate relationship between serum level of brain natriuretic peptide (BNP)and short-term prognosis in patients with acute myocardial infarction(AMI).Methods Ninetynine patients with AMl with elevated S-T segment in electrocardiogram admitted to the department of cardiology,the Fourth Hospital of Jilin University,Changchun during January to December 2008 were divided into two groups.one with percutaneous transluminal coronary angioplasty(PTCA)or pereutaneous coronary intervention(PCI)(61 eases)and the other without PTCA(38 cases)as controls.Their serum levels of BNP were measured at admission, and one day and seven days after admission,respectively,and their main adverse cardiac events(MACE)were followed-up and recorded for 30 days.Results No significant differenee in serum BNP level between the patients at admission and one day after admission was found(P＜0.01).Seven days after admission,serum BNP level in PCI group was significantly lower than that in controls(P＜0.01),and occurrence of MACE was significantly lower in PCI group than that in controls(P＜0.05).Logistic regression analysis indicated that serum BNP level in PCI group seven days after admission was the uppermost predictor for MACE in patients with AMI in one month after onset(OR=1.026,95%CI 1.014-1.038,P＜0.01).Serum BNP level was significantly higher in patients with MACE seven days after admission than that in those without it(P＜0.01)during 30-day followup.Conclusion Serum level of BNP seven days after admission is associated with their short-term prognosisfor patients with AMI.     

Outcomes after primary coronary intervention with drug-eluting stent implantation in diabetic patients with acute ST elevation myocardial infarction

Background Drug-eluting stent (DES) has been used widely for the treatment of patients with acute coronary syndrome with or without diabetes mellitus during percutaneous coronary intervention (PCI), but its long-term safety and efficacy in diabetic patients with acute ST elevation myocardial infarction (STEMI) remain uncertain. This study aimed to investigate the clinical outcomes after primary coronary intervention with DES implantation for diabetic patients with acute STEMI, compared with non-diabetic counterparts. Methods From December 2004 to March 2006, 56 consecutive diabetic patients (diabetic group) and 170 non-diabetic patients (non-diabetic group) with acute STEMI who underwent primary PCI with DES implantation in 3 hospitals were enrolled. Baseline clinical, angiographic, and procedural characteristics, as well as occurrence of major adverse cardiac event (MACE) including cardiac death, non-fatal recurrent myocardial infarction (re-MI) and target vessel revascularization (TVR) during hospitalization and one-year clinical follow-up were compared between the two groups. Results Patients in diabetic group were more hyperlipidemic (69.6% and 51.8%, P=0.03) and had longer time delay from symptom onset to admission ((364±219) minutes and (309±223) minutes, P=0.02) than those in non-diabetic group. The culprit vessel distribution, reference vessel diameter, and baseline TIMI flow grade were similar between the two groups, but multi-vessel disease was more common in diabetic than in non-diabetic group (82.1% and 51.2%, P&lt;0.001). Despite similar TIMI flow grades between the two groups after stenting, the occurrence of TIMI myocardial perfusion grade (TMPG) ≥2 was lower in diabetic group (75.0% vs 88.8% in non-diabetic groups, P=0.02). The MACE rate was similar during hospitalization between the two groups (5.4% vs 3.5%, P=0.72), but it was significantly higher in diabetic group (16.1%) during one-year follow-up, as compared with non-diabetic group (6.5%, P=0.03). The cumulative one-year MACE-free survival rate was significantly lower in diabetic than in non-diabetic group (78.6% vs 90.0%, P=0.02). Angiographic stent thrombosis occurred in 5.4% and 1.2% of the patients in diabetic and non-diabetic group, respectively (P=0.19). All of these patients experienced non-fatal myocardial infarction.Conclusions Although the early clinical outcomes were similar in diabetic and non-diabetic patients with acute STEMI treated with DES implantation, the cumulative MACE-free survival at one-year follow-up was worse in diabetic than in non-diabetic patients. More effective diabetes-related managements may further improve the clinical outcomes of diabetic cohort suffering STEMI.     

Efficacy of stenting for unprotected left main coronary artery disease in 297 patients

Background Angioplasty in the unprotected left main coronary artery （LMCA） has been controversial. This study aims to evaluate the safety and clinical effectiveness of stenting, including bare metal stent and drug eluting stent （DES）, for treatment of unprotected LMCA disease. Methods Between September 1997 and December 2005, a total of 297 consecutive patients underwent percutanous coronary intervention （PCI） on LMCA lesions in our hospital. Their in-hospital data and clinical follow-up outcomes were analyzed and those in pre-DES ＂＇era＂ （group I, from September 1997 to December 2002） were compared with those in DES ＂era＂ （group Ⅱ, from January 2003 to December 2004. Patients in 2005 for the time of follow-up less than one year were not included in this group）. Results Altogether 368 coronary stents were successfully deployed in 295 patients. Stents failed to be implanted after balloon predilation in two patients, who received coronary artery bypass graft （CABG） successfully. Bifurcation techniques for distal LMCA executed in 206 patients （69.4%, 2061297）, included crossover stenting in 156 （75.7%）, T stenting in 4 （1.9%）, provisional T stenting in 28 （13.6%）, kissing stenting in 5 （2.4%） and stent crushing in 13 （6.3%） patients. During their hospital stay, 5 （1.7%） patients died after PCI procedure, of which 4 died from cardiac origin and one of renal failure. The total in-hospital major adverse cardiac events （MACE） were 2.0% （6/297）. In the follow-up period, 19 patients （6.5%） died [15 （5.1%） of cardiac death and 4 of non-fatal myocardial infarction （MI）]. Besides, 2 （0.7%） developed subacute thrombosis （SAT） and 16 （5.4%） performed target lesion revascularization （TLR）. The total follow-up MACE was 14.5% （431297）. Further analysis also showed that, compared with patients in group I, those in group II apparently had more multi-vessel involvement （14.7% vs 81.9%, P〈0.001）, and more bifurcation lesions （32.4% vs 72.2%, P〈0.001）. After PCI, in-hospital MACE of group II was significantly lower than that in group I （1.1% vs 9.4%, P〈0.05）. And the incidences of MACE, TLR and angiographic restenosis in group II were all significantly lower than those in group I （all P〈0.05） after one year follow-up. Conclusions As new PCI strategies and intervention devices such as DES are developed, coronary stenting, which might have brought better in-hospital and long-term outcomes than CABG are proved to be technically successful and can be safely applied for the treatment of LMCA lesions in the experienced center for coronary intervention.     

麻疹的双相移位研究进展

近年新生儿、婴儿、成人麻疹患者逐年增加,临床表现一般仍较典型,成年人麻疹患者全身中毒症状较重。麻疹抗体检测结果阳性是主要的诊断依据。麻疹发病的双相移位的机理可能是,免疫保护力不足,婴儿出生时麻疹抗体力低。孕期母传胎的麻疹抗体减弱,母经乳汁传给婴儿的抗体减弱,成人麻疹抗体水平逐年下降。预防措施是怀孕前给予育龄妇女麻疹疫苗接种,鼓励母乳喂养,麻疹疫苗计划免疫适当提前,在成人追加麻疹疫苗的免疫,加强病毒变异的研究等。     

尿液pH值对红细胞检验影响的探讨

[目的 ]通过尿液 pH值对红细胞检验影响的观察 ,更加科学、准确地诊断血尿和血红蛋白尿。[方法 ]采用干化学分析仪检测和尿液显微镜红细胞计数 ,观察 180例正常人尿标本加入正常人血标本后 ,不同 pH值 ,不同时间内 ,观察红细胞溶解情况。 [结果 ]pH <5 .5以下时 ,随着时间的延长 ,红细胞溶解现象明显。 1h后观察有显著性差异 (P <0 .0 5 ) ;2h后有非常显著性差异 (P <0 .0 1)。[结论 ]pH <5 .5时对红细胞计数影响较大 ,易致红细胞发生溶解现象 ,出现假性血红蛋白尿 ,对血尿和血红蛋白尿很难区分 ,给临床诊断造成不便 ,更易引起漏诊和误诊。     

醋柳黄酮缓释片的药动学初步研究

目的:研究醋柳黄酮缓释片在家犬体内的药动学过程,测定其药动学参数,计算缓释片相对于普通片的生物利用度。方法:将实验动物分为两组,分别用醋柳黄酮缓释片和普通片进行口服给药,用高效液相色谱法测定血浆药物浓度,应用3P97软件求算药动学参数。结果:醋柳黄酮缓释片及普通片的tm ax分别为4.87 h和2.87 h,Cm ax分别为每小时0.46μg.L-1和每小时0.56μg.L-1,缓释片的相对生物利用度为111.7%。结论:醋柳黄酮缓释片与普通片均符合一室模型,缓释片与普通片具有生物等效性,且醋柳黄酮缓释片有明显的缓释效果。     

主动脉窦瘤破裂的外科治疗

报告２０例主动脉窦瘤破裂修复术的结果。１７例男性，３例女性。年龄７～５６岁。痊愈１９例，另一例因急性肾功能衰竭一周后死亡。作者就发病机理，诊断和合并畸形的处理进行了讨论。     

正常增殖期子宫内膜细胞增生状态的定量观察

以＾３氢－胸腺嘧啶核苷放射自显影法及ＨＥ染色，观察并分别测定了１８例正常子宫内膜增殖中期，１５例增殖晚期的腺上皮细胞或间质细胞的标记指数、分裂指数。结果显示：子宫内膜增殖晚期腺上皮细胞或间质细胞之ＬＩ均明显高于增殖中期。同时，增殖晚间质细胞之ＭＩ也明显高于增殖中期，即此两种细胞在增殖晚期中增生明显，其增生状态初步获得了定位定量测定的正常值。     

腰椎间盘突出症再次手术的原因分析

目的解决腰椎间盘突出症手术中神经压迫。方法对1980～1998年再手术资料进行统计分析,讨论分析再手术原因,再次手术前影像学检查,观察病理变化以确定再手术方法。结果对11例随访6个月～1年,优7例(68．4％),良3例(36．8％),差1例(2．8％)。结论初次手术前详细查体和分析X线片,术中用导尿管和神经剥离探查,尽量避免髓核遗留,手术范围不宜太大,尽量减少对软组织和脊柱结构的破坏,避免形成硬膜囊与神经根粘连而致单纯形疤痕。     

扩张兔皮肤超微结构的变化

目的：动态观察扩张兔皮肤超微结构的变化。方法：选用2--3kg新西兰大白兔64只，分为2大组，快速扩张组和常规扩张组，每组32只，每大组再分为4组，为扩张完成后即时、1周、12周、24周组。每组8只，其中4只为实验组，另4只植入扩张器不扩张作为对照组。透射电子显微镜观察各组皮肤超微结构的变化。结果：表皮扩张后经历--由扩张刺激引起的创伤至完全修复的过程。扩张后即时真皮中成纤维细胞大量增生，功能由静止转向活跃，胶原纤维碎裂成片，弹力纤维部分断裂，炎症细胞浸润；扩张后1周常规扩张组基底膜连续性基本恢复。显示成纤维细胞合成功能活跃。扩张后12周、24周，成纤维细胞趋于稳定、形态狭长，部分胶原排列紊乱，部分有似癜痕样改变。结论：扩张刺激可致兔皮肤创伤。扩张后真皮不可完全修复。     

芹黄素对大鼠缺血视网膜功能恢复的作用

目的观察芹黄素对大鼠缺血视网膜功能恢复的作用。方法30只Long-Evans大鼠用动脉结扎法造成视网膜缺血模型,其中治疗组20只腹腔注射芹黄素,对照组10只注射溶媒二甲基亚酚。用视觉电生理仪检查视网膜功能恢复情况。结果芹黄素治疗组视网膜功能恢复明显好于对照组(P<0.05)。结论芹黄素能促进大鼠缺血视网膜的功能恢复。      

上颌骨牙源性囊肿刮除手术的疗效观察

目的探讨对上颌骨牙源性囊肿患者进行囊肿彻底刮除手术的临床疗效。方法对我科在2010年1月～2017年9月收治的73例上颌骨牙源性囊肿患者行囊肿彻底刮除手术治疗,对患者术区肿胀消退、术后伤口感染、伤口愈合、牙龈再附着、术后复发、骨质改建、骨质修复等情况随访观察。结果 73例患者术后肿胀消退时间为1～4 d。73例患者术后均未发生伤口感染,伤口均一期愈合。所有患者牙龈再附着情况好,术后均未见复发。术后未见并发症。骨质改建效果好,骨质修复的效果因影像学资料过少,缺乏客观依据,暂不下有效结论。结论对上颌骨牙源性囊肿患者进行囊肿彻底刮除手术,术后患者的恢复情况良好,值得在临床治疗上进行推广。     

阴道炎1236例病原检查分析

对１２３６例阴道炎患者的阴道分泌物作直接镜检和病原菌分离培养检查；结果，细菌感染９００例，念珠菌２３４例，滴虫１０２例。９００例细菌经鉴定；葡萄球菌３００例，阴道加特纳菌２７６例，淋病奈瑟菌１７０例，其它细菌１２４例。结果表明，葡萄球菌，阴道加特纳菌，淋病奈瑟菌是细菌性阴道炎最常见的致病菌。